Fig. 1From: Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutationsa. Progression free survival according to TKI received. b. Overall survival according to TKI receivedBack to article page